Biovica refocuses US commercial strategy and terminates agreement with Tempus AI
Biovica refocuses US commercial strategy and terminates agreement with Tempus AI
Biovica, specializing in blood-based cancer monitoring, today announces that it has, by mutual agreement, ended the reference laboratory agreement with Tempus AI, Inc., announced in May 2025. Under the agreement, Tempus was intended to offer DiviTum® TKa as part of its diagnostic portfolio to its network of oncologists in the United States. The collaboration did not progress to commercial launch and did not generate revenue for Biovica.
Following a review of its US commercial strategy, Biovica has decided, following conversations with Tempus, to end the collaboration and redirect its resources toward commercial channels with a clearer path to near-term adoption and revenue generation. The company will continue to evaluate partnership opportunities that can support broader adoption of DiviTum TKa in the US market.
“We entered into the agreement with Tempus with strong conviction in its potential. However, more than a year after the agreement was announced, the collaboration had not resulted in a commercial launch, patient access or revenue,” said Theis Kipling, CEO of Biovica. “As we sharpen our US commercial strategy, we have concluded that this is the right time to end the collaboration and focus our resources on the opportunities where we see the clearest path to commercial adoption.”
The end of the agreement does not affect Biovica’s CLIA/CAP-accredited laboratory operations in San Diego or its existing US clinical activities or its Pharma Services business.
Biovica will provide further updates regarding its US commercial strategy as appropriate.